Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation.
Desai
D M
DM
Department of Surgery, Stanford University School of Medicine, Palo Alto, CA 94304, USA.
Scandling
J D
JD
Knoppel
C
C
Dafoe
D C
DC
Alfrey
E J
EJ
D000328:Adult; D002140:California; D003365:Costs and Cost Analysis; D005260:Female; D006084:Graft Rejection / Q000191:economics / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000191:economics / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000191:economics / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology*; D011183:Postoperative Complications; D012074:Remission Induction; D012189:Retrospective Studies
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3